Why the Recce (ASX:RCE) share price is racing 5% higher today

This ASX share is off to a flying start this week…

| More on:
A medical researcher in a white coat holds laboratory equipment and smiles.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is on the move today. It comes after the pharmaceutical company provided a patent update on its synthetic anti-infectives.

At the time of writing, the Recce share price is up 5.73% to $1.015. In comparison, the All Ordinaries Index (ASX: XAO) is down 0.65% to 7,238 points.

What's pushing the Recce share price higher?

The Recce share price is pushing higher today after the Chinese Patent Office granted Patent Family 3 to Recce anti-infectives. Titled 'Anti-virus Agent and Method for Treatment of Viral Infection', the patent allows marketing and manufacturing monopolies until February 2037.

According to the company's update, the granted claims relate to antibiotic drug Recce 327 and the new anti-viral formulation Recce 529.

China is considered one of the largest pharmaceutical markets in the world, valued at roughly US$86.74 billion. This places the lucrative Chinese market behind the United States and Japan in terms of revenue size.

The latest patent approval in Family 3 follows recent patent grants in Europe and Japan.

The country witnesses millions of cases where infections are caused by lipid enveloped or coated viruses. Patent Family 3 applications in other major pharmaceutical markets around the world are in their own advanced stages of independent patent reviews.

Recce CEO James Graham commented:

Recce's intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis before us. With this new patent granted in one of the largest pharmaceutical markets in the world, our market monopolies reinforce the unique opportunities among a significant range of both bacterial and viral pathogens.

About the Recce share price

Recce is involved in the advancement of synthetic antibodies designed to address the global health challenge of antibiotic-resistant superbugs. The medical company's flagship drug Recce 327 is being developed to treat blood infections and sepsis.

The group operates solely in research and development in both Australia and the United States.

The Recce share price has fallen by more than 25% in the past 12 months and 3.3% year-to-date. The company's shares hit a 52-week low of 86 cents in late June after weak investor sentiment kicked in.

At today's price, Recce commands a market capitalisation of around $177 million, with roughly 173.7 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young man in a city street with a hopeful look on his face.
Share Market News

Here are the top 10 ASX 200 shares today

It was a return to form for ASX 200 shares this Thursday.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Broker Notes

Morgans names 3 ASX stocks to buy following results

Here are three stocks that Morgans is feeling bullish on this week.

Read more »

A man stands in a building site featuring brick walls with building equipment in the background.
Mergers & Acquisitions

CSR share price jumps again as blockbuster bid confirmed

Investors are excited about a potential takeover.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Share Gainers

Why Bega Cheese, Domino's, Lovisa, and Universal Store shares are rocketing today

These ASX shares are catching the eye on Thursday. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Clinuvel, Medibank, Sayona Mining, and Tabcorp shares are sinking today

These ASX shares are out of favour with investors on Thursday. But why?

Read more »

rising asx share price represented by drone flying in the air
Technology Shares

How has the DroneShield share price gained 90% in a month?

DroneShield shares are once again at a new record high today.

Read more »

Woman smiles at camera at she buys greens from the supermarket.
Broker Notes

Are Woolworths shares dirt cheap following the selloff?

Is now the time to pounce? Let's see what one leading broker thinks.

Read more »

A bored woman looking at her computer, it's bad news.
Share Market News

Sayona Mining share price crashes 19% after Piedmont Lithium says sayonara

This lithium miner's shares are taking a beating on Thursday.

Read more »